From June 2002 until August 2005, Dr. Freddo served as executive director and site therapeutic area leader for oncology clinical development in La Jolla. While at Pfizer, Dr. Freddo led the team responsible for the registration of Sutent(R) (sunitinib malate), a drug approved by the U.S. Food and Drug Administration in January 2006 for the treatment of advanced kidney cancer and gastrointestinal stromal tumors. Prior to joining Pfizer, Dr. Freddo held a variety of senior management positions at Wyeth-Ayerst Research from December 1996 until June 2002, including senior director, oncology, senior director, infectious diseases, and senior director, transplantation immunology.